Clinical Trials Logo

Hyperlipidemia clinical trials

View clinical trials related to Hyperlipidemia.

Filter by:

NCT ID: NCT05260411 Recruiting - Hyperlipidemia Clinical Trials

A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Start date: January 26, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase # clinical study evaluating the efficacy and safety of AK102 Q6W in patients with primary hypercholesterolemia and mixed hyperlipidemia.

NCT ID: NCT05255458 Recruiting - Hyperlipidemia Clinical Trials

A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Start date: November 4, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

NCT ID: NCT05255094 Recruiting - Hyperlipidemia Clinical Trials

A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Start date: November 3, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled phase Ⅲ clinical study evaluating the efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.

NCT ID: NCT04998981 Recruiting - Hyperlipidemia Clinical Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

Start date: September 17, 2021
Phase: Phase 3
Study type: Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients with High TG and Low HDL-C

NCT ID: NCT04977583 Completed - Hypertension Clinical Trials

Unmet Social Needs Study

Start date: May 2, 2022
Phase: N/A
Study type: Interventional

The impacts of unmet social needs, such as homelessness, inconsistent access to food, and exposure to violence on health are well-established, especially for cardiovascular disease. A limited but growing body of evidence suggests that screening for and addressing these needs - also referred as social determinants of health -- in clinic settings helps to connect patients to resources to address unmet needs and has the potential to improve health outcomes. Veterans carry a high burden of unmet needs. At present, VA systematically screens for only two unmet needs; homelessness and food insecurity. The investigators propose to assess the efficacy of systematically screening Veterans for nine unmet needs (i.e., housing, food insecurity, utility insecurity, transportation, legal problems, employment, safety, stress, and social isolation), and compare the effect of referral mechanisms of varying intensity on Veterans' connection to resources, reduction of unmet needs, treatment adherence, reduced preventable hospitalizations, and clinical outcomes.

NCT ID: NCT04774003 Completed - Hyperlipidemia Clinical Trials

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

ORION-14
Start date: February 26, 2021
Phase: Phase 1
Study type: Interventional

Study to evaluate the pharmacokinetics and pharmacodynamics of inclisiran treatment given as single subcutaneous injection in Chinese participants with elevated low-density lipoprotein cholesterol (LDL-C) despite treatment with LDL-C lowering therapies

NCT ID: NCT04692025 Completed - Healthy Clinical Trials

Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers

Start date: December 27, 2020
Phase: Phase 1
Study type: Interventional

This study is to evaluate the effect of food on the pharmacokinetics of a single dose of ASC41 tablet in healthy volunteers, comparing fasting and postprandial pharmacokinetic parameters of Tmax, Cmax, AUC0-t, AUC0-∞.

NCT ID: NCT04686994 Completed - Clinical trials for Overweight and Obesity

Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

Start date: December 22, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .

NCT ID: NCT04673721 Completed - Obesity Clinical Trials

PROSPective Evaluation of Fortified Eggs Related to Improvement in The Biomarker Profile for Your Health

PROSPERITY
Start date: January 6, 2021
Phase: N/A
Study type: Interventional

The objective of the study is to assess the effect of fortified eggs (compared to a non-egg supplemented diet) and intermittent fasting (IF) (compared to a usual care diet) on biomarker profile at 4 months. This will be a 140-participant, 2x2 factorial, randomized clinical trial comparing fortified eggs vs. a non-egg supplemented diet and IF vs. usual care diet through 4 months. Participants will be randomized 1:1:1:1 to the four treatment groups. Participants will have in-person follow-up visits at 1- and 4- months (inclusive of laboratory assessments) in addition to telephone calls at months 2 and 3. A subset of patients (~24 in each egg randomized strata) will undergo microbiome assessment at baseline and at 4 months.

NCT ID: NCT04672278 Completed - Hypertension Clinical Trials

Lipid-Lowering Effect and Hypotensive Effect of Shanzha Fruit Drink in Patients

Start date: January 2, 2019
Phase: N/A
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, cross-over study. Subjects who meet the inclusion/exclusion criteria will be randomly and alternatively assigned to receive Shanzha fruit drink or placebo drink in the first 2 months or the last two months of the 5 months study period. In between the first and second treatment period, all patients will enter a Washout Period of 4 weeks and during which time patients should not receive any of the study functional fruit drink.